Quantification of p53 in epithelial ovarian cancer

Gynecologic Oncology

Volumn 66, Issue 3, 1997, Pages 435-438

  Geisler, John P ^a   Geisler, Hans E ^a   Wiemann, Michael C ^a   Givens, Stanley S ^a   Zhou, Zhen ^b   Miller, Greg A ^b  

^a ST VINCENT HOSPITAL   (United States)

^b Dept of Pathol Lab for Diagn ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL PROLIFERATION; CYSTADENOCARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE DIAGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

EID: 0031239888     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4799     Document Type: Article

References (15)

1. 1. Purdie CA, O'Grady J, Piris J, Wyllie AH, Bird CC: p53 expression in colorectal tumors. Am J Pathol 138:807-813, 1991
2. 2. Levine AJ: The role of p53 as a tumor suppressor gene in human cancers. Adv Oncol 8:3-9, 1993
3. 3. Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC Jr: The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 170:246-252, 1994
4. 4. Bur ME, Perlman C, Edelmann L, Fey E, Rose PG: p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 98:81-87, 1992
5. 5. Ambros RA, Vigna PA, Figge J, Kallakury BVS, Mastrangelo A, Eastman AY, Malfetano J, Figge HL, Ross JS: Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. Cancer 73:1686-1692, 1994
6. 6. Geisler JP, Zhou Z, Miller GA, Wiemann MC, Geisler HE: p53 as a prognostic indicator in endometrial cancer. Gynecol Oncol 61:245-248, 1996
7. 7. Reinartz JJ, George E, Lindgren BR, Niehans GA: Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 25:1075-1083, 1994
8. 8. Azumi N, Czernobilsky B: Immunohistochemistry, in Kurman RJ (ed): Blaustein's Pathology of the Female Genital Tract. New York, Springer Verlag, 1994, 4th ed, pp. 1131-1160
9. 9. Gallion HH, Pieretti M, DePriest PD, van Nagell JR Jr: The molecular basis of ovarian cancer. Cancer 76:1201-1208, 1995
10. 10. Mujoo K, Maneval DC, Anderson SC, Gutterman JU. Oncogene 12:1617-1623, 1996
11. 11. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, Soper JT, Bast RC Jr, Berchuck A: Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85:1513-1519, 1993
12. 12. Kohler MF, Carney P, Dodge R, Soper JT, Clarke-Pearson DL, Marks JR, Berchuck A: p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol 175:1246-1252, 1996
13. 13. Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmondson JH, Grill JP, Su JQ, Katzmann JA, Roche PC: Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 12:64-69, 1994
14. 14. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC Jr, Berchuck A: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51:2979-2984, 1991
15. 15. Klemi PJ, Pylkkanen L, Kiilholma P, Kurvinen K, Joensuu H: p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76:1201 -1208, 1995